15 results

  • amjevita

    (adalimumab-atto)
    Amgen Inc
    AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

  • avsola

    (infliximab-axxq)
    Amgen Inc
    AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining remission in moderately to severely active Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), and other conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.

  • cimzia

    (certolizumab pegol)
    UCB, Inc.
    CIMZIA is indicated for treating moderate to severe Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults and eligible pediatric patients aged 2 years and older.

  • cyltezo

    (adalimumab-adbm)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

  • enbrel

    (etanercept)
    Immunex Corporation
    Enbrel is indicated for reducing symptoms and structural damage in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic moderate to severe plaque psoriasis, and active juvenile psoriatic arthritis in patients 2 years and older. It may be used alone or with methotrexate.

  • hadlima

    (adalimumab-bwwd)
    Organon LLC
    HADLIMA is indicated for various conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It alleviates symptoms, improves function, and may inhibit disease progression, used alone or with other treatments.

  • hulio

    (adalimumab-fkjp)
    Mylan Specialty L.P.
    HULIO is indicated for reducing signs and symptoms, and improving function in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and children over 2 years.

  • humira

    (Adalimumab)
    AbbVie Inc.
    HUMIRA is indicated for reducing signs and symptoms and improving physical function in various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and children.

  • hyrimoz

    (adalimumab-adaz)
    Sandoz Inc
    HYRIMOZ is indicated for adults with moderate to severe chronic plaque psoriasis who require systemic therapy or phototherapy, and when other therapies are unsuitable. Patients must be monitored closely with regular physician follow-ups.

  • inflectra

    (infliximab-dyyb)
    Pfizer Laboratories Div Pfizer Inc
    INFLECTRA is indicated for treating moderately to severely active Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults and pediatric patients aged 6 and older, particularly in cases unresponsive to conventional therapies.